CARMAT | Sales 2023 | 2.8M 3.04M | Sales 2024 * | 14.85M 16.11M | Capitalization | 87.5M 94.91M |
|---|---|---|---|---|---|
| Net income 2023 | -53M -57.49M | Net income 2024 * | -38M -41.22M | EV / Sales 2023 | 59.2 x |
| Net Debt 2023 * | 49.63M 53.83M | Net Debt 2024 * | 61.25M 66.43M | EV / Sales 2024 * | 10 x |
| P/E ratio 2023 |
-3.09
x | P/E ratio 2024 * |
-2.2
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 78.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Carmat
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Piat
CEO | Chief Executive Officer | - | 16-08-31 |
Alain Carpentier
FOU | Founder | 91 | 08-06-24 |
| Director of Finance/CFO | - | 18-12-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexandre Conroy
CHM | Chairman | 61 | 22-12-21 |
| Director/Board Member | 85 | 16-04-11 | |
Pierre Bastid
BRD | Director/Board Member | 69 | 18-04-04 |
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
2024-05-29
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +12.01% | 128B | |
| -8.43% | 11.26B | |
| +6.26% | 9.28B | |
| +35.53% | 5.42B | |
| +8.68% | 3.45B | |
| -8.89% | 2.8B | |
| -10.68% | 2.1B | |
| -10.77% | 1.98B | |
| -26.31% | 1.71B |
